Figure 8. In vivo tumor targeting evaluation.

(A) T₂WI and T₂-mapping images of mice bearing Bel-7402 subcutaneous tumors before and after tail vein administration of RGD-PEG-g-PEI-SPION or PEG-g-PEI-SPION. (B) The normalized MR signal intensity of the tumors before and after tail vein administration of the various complexes. (C) T₂ values of the tumors before and after tail vein administration of the various complexes. (means±SD; n = 5).